{"id":"NCT03493854","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","officialTitle":"A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-14","primaryCompletion":"2019-07-04","completion":"2023-06-02","firstPosted":"2018-04-11","resultsPosted":"2020-06-25","lastUpdate":"2024-06-26"},"enrollment":500,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Early Breast Cancer"],"interventions":[{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Pertuzumab IV","otherNames":["Perjeta","RO4368451"]},{"type":"DRUG","name":"FDC of Pertuzumab and Trastuzumab SC","otherNames":["Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","RO7198574","RG6264"]},{"type":"DRUG","name":"Trastuzumab IV","otherNames":["Herceptin","RO0452317"]},{"type":"DRUG","name":"Trastuzumab SC","otherNames":["Herceptin","RO0452317"]},{"type":"PROCEDURE","name":"Surgery","otherNames":[]},{"type":"RADIATION","name":"Post-operative Radiotherapy","otherNames":[]},{"type":"DRUG","name":"Hormone Therapy","otherNames":[]}],"arms":[{"label":"Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy","type":"ACTIVE_COMPARATOR"},{"label":"Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy","type":"EXPERIMENTAL"}],"summary":"This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.","primaryOutcome":{"measure":"Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)","timeFrame":"Pre-dose on Cycle 8, Day 1 (up to 21 weeks)","effectByArm":[{"arm":"Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy","deltaMin":72.4,"sd":34.1},{"arm":"Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy","deltaMin":88.7,"sd":33.6}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":23},"locations":{"siteCount":107,"countries":["United States","Argentina","Belgium","Brazil","Canada","Czechia","France","Germany","Italy","Japan","Mexico","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["33357420"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":252},"commonTop":["Alopecia","Nausea","Diarrhoea","Anaemia","Asthenia"]}}